Tech Company Financing Transactions
PharmaCyte Biotech Funding Round
On 9/2/2025, PharmaCyte Biotech raised $3 million in financing from private investors.
Transaction Overview
Company Name
Announced On
9/2/2025
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3960 Howard Hughes Parkway 500
Las Vegas, NV 89169
USA
Las Vegas, NV 89169
USA
Phone
Website
Email Address
Overview
PharmaCyte is a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box, for potential development of cellular therapies for cancer, diabetes and malignant ascites. PharmaCyte's candidate therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are to be implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) will be given intravenously at one-third the normal dose.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Silverman
Browse more venture capital transactions:
Prev: 9/2/2025: Professional.me venture capital transaction
Next: 9/2/2025: Tangany venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs